Incidence of anaphylaxis to YF-VAX(R) yellow fever vaccination: a retrospective evaluation of vaccine adverse event reports 1999-2018.

HOME
>
論文・技術情報
>
Incidence of anaphylaxis to YF-VAX(R) yellow fever vaccination: a retrospective evaluation of vaccine adverse event reports 1999-2018.

Incidence of anaphylaxis to YF-VAX(R) yellow fever vaccination: a retrospective evaluation of vaccine adverse event reports 1999-2018.

アブストラクト	BACKGROUND: The incidence of anaphylaxis after receipt of yellow fever (YF) vaccine is highly variable based upon previously published reports. Anaphylaxis after receiving the YF vaccine has been reported to range from 0 up to 22 per 1 000 000 doses. Our clinical experience suggested increased incidence, which prompted our investigation. We sought to evaluate the current incidence rate of anaphylaxis after receipt of the 17D-204 strain YF-VAX(R) brand reported in the US. METHODS: We performed a retrospective review of the Vaccine Adverse Event Reporting System (VAERS) reports of anaphylaxis after receiving the YF-VAX vaccine occurring between 1 October 1999 and 30 September 2018. We utilized the Brighton Collaboration Case Definition and inclusion determination was made by a board-certified allergist. We also obtained the total number of YF-VAX doses distributed across the US during this same time-period and then calculated an updated incidence rate of YF-VAX vaccine-associated anaphylaxis. RESULTS: We identified 132 potential cases of possible or probable anaphylaxis. Of these, 111 met inclusion criteria: level 1 (n = 51), level 2 (n = 59) and level 3 (n = 1). The manufacturer reported a total distribution of 7 624 160 doses of YF-VAX from 1 October 1999 to 30 September 2018. The calculated incidence rate of YF-VAX vaccine-associated anaphylaxis is estimated at 14.6 events per 1 000 000 doses. CONCLUSIONS: We conclude the estimated rate of anaphylaxis per VAERS reports is 14.6 events per 1 000 000 doses after YF-VAX vaccination. This is consistent with some previous reports and substantially higher than rates of anaphylaxis after other vaccines.
ジャーナル名	Journal of travel medicine
Pubmed追加日	2023/12/6
投稿者	McClenathan, Bruce M; Taylor, Jillian N; Housel, Laurie A; Ryan, Margaret
組織名	Immunization Healthcare Division, South Atlantic Region Vaccine Safety Hub,;Defense Health Agency, Fort Liberty, NC, USA.;Department of Medicine, Womack Army Medical Center, Fort Liberty, NC, USA.;Campbell University School of Osteopathic Medicine, Lillington, NC, USA.;Immunization Healthcare Division Pacific Region Vaccine Safety Hub, Defense;Health Agency, San Diego, CA, USA.;Naval Medical Center, San Diego, CA, USA.
Pubmed リンク	https://www.ncbi.nlm.nih.gov/pubmed/38051650/